LONDON, May 20 (Reuters) – Roche’s breast cancer
drug Perjeta, or pertuzumab, has been turned down for use on
Britain’s state health service, making it the latest in a number
of pricey new cancer…
The post Roche breast cancer drug Perjeta rejected by UK cost agency appeared first on NASDAQ.